379 related articles for article (PubMed ID: 33196778)
1. Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept.
Hong HK; Park YJ; Kim DK; Ryoo NK; Ko YJ; Park KH; Kim HM; Woo SJ
Invest Ophthalmol Vis Sci; 2020 Nov; 61(13):22. PubMed ID: 33196778
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization.
Crespo-Garcia S; Corkhill C; Roubeix C; Davids AM; Kociok N; Strauss O; Joussen AM; Reichhart N
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):4997-5006. PubMed ID: 28979997
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2.
Jiang J; Xu K; Wang L; Xin W; Zhao G; Huang M; Li S; Luan X; Fang J
Eur J Pharm Sci; 2018 Aug; 121():251-259. PubMed ID: 29715501
[TBL] [Abstract][Full Text] [Related]
4. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Seo S; Suh W
Mol Vis; 2017; 23():823-831. PubMed ID: 29225458
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
[TBL] [Abstract][Full Text] [Related]
8. Retinal vascular changes and aqueous humor cytokines changes after aflibercept intravitreal injection in treatment-naïve myopic choroidal neovascularization.
Di Antonio L; Toto L; Mastropasqua A; Brescia L; Erroi E; Lamolinara A; Di Nicola M; Mastropasqua L
Sci Rep; 2018 Oct; 8(1):15631. PubMed ID: 30353107
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept efficacy in refractory choroidal neovascularization.
Brănişteanu DC; Bîlhă A; Moraru A
Rom J Ophthalmol; 2016; 60(2):96-102. PubMed ID: 29450330
[TBL] [Abstract][Full Text] [Related]
12. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
[TBL] [Abstract][Full Text] [Related]
13. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
15. Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.
Romdhane K; Zola M; Matet A; Daruich A; Elalouf M; Behar-Cohen F; Mantel I
Br J Ophthalmol; 2020 Jul; 104(7):910-916. PubMed ID: 31615761
[TBL] [Abstract][Full Text] [Related]
16. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
Fauser S; Muether PS
Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
[TBL] [Abstract][Full Text] [Related]
17. Different effects of anti-VEGF drugs (Ranibizumab, Aflibercept, Conbercept) on autophagy and its effect on neovascularization in RF/6A cells.
Wang Y; Yao Y; Li R; Wu B; Lu H; Cheng J; Liu Z; Du J
Microvasc Res; 2021 Nov; 138():104207. PubMed ID: 34119535
[TBL] [Abstract][Full Text] [Related]
18. A Sema3C Mutant Resistant to Cleavage by Furin (FR-Sema3C) Inhibits Choroidal Neovascularization.
Toledano S; Lu H; Palacio A; Ziv K; Kessler O; Schaal S; Neufeld G; Barak Y
PLoS One; 2016; 11(12):e0168122. PubMed ID: 28036336
[TBL] [Abstract][Full Text] [Related]
19. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
20. Blockage of PI3K/mTOR Pathways Inhibits Laser-Induced Choroidal Neovascularization and Improves Outcomes Relative to VEGF-A Suppression Alone.
Ma J; Sun Y; López FJ; Adamson P; Kurali E; Lashkari K
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3138-44. PubMed ID: 27304845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
